LUPS-Lipids and Glucose Under Prospective Surveillance

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
City of Hamburg
Universitätsklinikum Hamburg-Eppendorf
Information provided by:
Asklepios proresearch
ClinicalTrials.gov Identifier:
NCT01313156
First received: March 10, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

Prospective, non-randomized cohort study to analyse genetic variations, dietary patterns, perceived stress and anxiety and early changes in lipid metabolism leading to the metabolic syndrome and type 2 diabetes


Condition
Metabolic Syndrome, Syndrome X, MetS,
Diabetes Mellitus, Non-Insulin-Dependent

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Lipids and Glucose Under Prospective Surveillance

Resource links provided by NLM:


Further study details as provided by Asklepios proresearch:

Primary Outcome Measures:
  • Metabolic Syndrome, Type 2 Diabetes [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    assessing risk factors, e.g. HDL, BMI, Blood Pressure, FPG


Enrollment: 1962
Study Start Date: November 2008
Estimated Primary Completion Date: May 2020 (Final data collection date for primary outcome measure)
Detailed Description:

The LUPS-study is a collaboration between Asklepios Clinics Hamburg GmbH and University Clinic Hamburg Eppendorf, Germany. This study is assessing a multitude of serum biomarkers, anthropometrics, dietary habits, physical activity, perceived stress along with genetic information from "healthy workers" (25-60years) to better understand phenotype-genotype associations leading to MetS and type 2 diabetes.

  Eligibility

Ages Eligible for Study:   25 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

so-called "Healthy-Workers", aged 25-60years, of Lufthansa-Technik, Hamburg, Germany, who voluntarily aggreed to participate in the study.

Criteria

Inclusion Criteria:

  • 25-60 years men and women willing to give consent

Exclusion Criteria:

  • diabetes (type 1 or 2)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01313156

Locations
Germany
Asklepios Klinik St.Georg
Hamburg, Germany, 20099
Universitätsklinikum Eppendorf
Hamburg, Germany, 20246
Sponsors and Collaborators
Asklepios proresearch
City of Hamburg
Universitätsklinikum Hamburg-Eppendorf
Investigators
Principal Investigator: Dirk Mueller-Wieland, Prof., MD Asklepios Klinik St.Georg, Hamburg, Germany
Principal Investigator: Karl Wegscheider, Prof., PHD Universitätsklinikum Hamburg Eppendorf, Germany
  More Information

No publications provided

Responsible Party: 1.Prof. Mueller-Wieland; 2.Prof.Wegscheider, 1.Asklepios Klinik St.Georg, I.Med.; 2. Universitätsklinikum HH-Eppendorf, Abtlg.f. Epidemiologie
ClinicalTrials.gov Identifier: NCT01313156     History of Changes
Other Study ID Numbers: AKS#1833
Study First Received: March 10, 2011
Last Updated: March 10, 2011
Health Authority: Germany: Ethics Commission

Keywords provided by Asklepios proresearch:
Metabolic Syndrome, Syndrome X, MetS,
Type 2 Diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Metabolic Syndrome X
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Resistance
Hyperinsulinism

ClinicalTrials.gov processed this record on April 17, 2014